Our Dealmaker’s Log tracks African private capital exits since 2023. Access the Dealmaker’s Log here
EXEO Capital has exited its investment in Chemical Process Technologies (CPT), a Pretoria-based manufacturer of active pharmaceutical ingredients (APIs) used in animal health products.
The transaction follows a four-year investment period by EXEO Capital’s Agri-Vie Fund II. The company has gained a new investor as shareholder.
EXEO Capital invested in CPT in 2022, initially acquiring a minority stake before later increasing its shareholding to a majority position through additional growth capital.
“CPT is a prime example of our approach to investing in specialised businesses where targeted capital, strategic support and operational improvements can unlock meaningful value,” says Denham Wiercx, senior associate at EXEO Capital. “From the outset, we were attracted to the company’s technical expertise, its role in local manufacturing and the opportunity to support a business operating in a highly specialised sector with significant barriers to entry.”
“Agri-Vie has been a supportive and constructive partner, helping us unlock opportunities that would have been difficult to pursue on our own,” says Gerrit van der Klashorst, executive director at CPT. “The investment enabled us to strengthen our operations, upgrade our manufacturing capabilities and build a stronger foundation for future growth. We are proud of what has been achieved during the partnership and excited about the opportunities that lie ahead.”
EXEO Capital and the CPT shareholders will retain their interests in CPT Pharma, which focuses on the development of APIs for human health applications. This business is being advanced as a separate long-term growth platform aimed at supporting the localisation of pharmaceutical manufacturing in Africa.
** For the best experience, download the free Africa Private Equity News app Android | iOS **